<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980665</url>
  </required_header>
  <id_info>
    <org_study_id>20170812V1</org_study_id>
    <nct_id>NCT03980665</nct_id>
  </id_info>
  <brief_title>The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART</brief_title>
  <official_title>The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating
      latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although combined antiretroviral therapy (cART) could control human immunodeficiency virus
      type 1 (HIV-1) infection, the persistence of HIV-1 viral reservoir make it extremely
      difficult to achieving cure of AIDS. The shock and kill strategy has been extensively
      practiced. The latency reversing agents (LRAs) could reactivate latent HIV-1 and then the
      reactivated virus could be eradicated. However, no appropriate activator has been found nor
      manufactured. Our previous work found that the arsenic trioxide, clinically approved for
      treating acute promyelocytic leukemia,could efficiently reactivate latent provirus in CD4+T
      cells from HIV-1 patients and Simian immunodeficiency virus (SIV)-infected macaques, without
      significant systemic T cell activation and inflammatory responses. In this study, we are
      going to study the safety of and efficacy of arsenic trioxide combined with cART in 20 HIV-1
      infected patients, by observing adverse events,HIV-1 reservoir, HIV-1 load, and some immune
      index.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The control arm includes HIV-infected patients with the therapy of Antiretroviral drugs.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events of arsenic trioxide combined with cART</measure>
    <time_frame>6 Months</time_frame>
    <description>To observe the adverse events of arsenic trioxide combined with cART when treating with HIV-infected patients during the clinical trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 reservoir</measure>
    <time_frame>6 Months</time_frame>
    <description>To assay the HIV-1 viral load in the peripheral blood Mono-nuclear cells and plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV-specific immunity</measure>
    <time_frame>6 Months</time_frame>
    <description>The number of HIV-specific CD4,CD8 and their activity after receiving arsenic trioxide</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Arsenic trioxide combined with cART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA &lt;50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without arsenic trioxide therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA &lt;50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia</description>
    <arm_group_label>Arsenic trioxide combined with cART</arm_group_label>
    <other_name>Arsenic Trioxide Injectable Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infection confirmed

          2. Receiving HAART more than 12 months.

          3. HIV viral-load &lt; 50 copies/ml and CD4+ cell count more than 350 cells/ul.

          4. Without serious heart, lung, liver or kidney disease.

          5. Participants know about the study and sign informed consent.

        Exclusion Criteria:

          1. With serious active HBV or HCV infection or opportunistic infections

          2. With serious chronic disease such as diabetes, mental illness,et al

          3. History of suffering from pancreatitis during HAART.

          4. Pregnant or breast-fed.

          5. With poor adherence.

          6. Unable to complete the follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Cai, Bachelor</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou 8th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linghua Li, Doctor</last_name>
    <phone>020-83710825</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weiping Cai, Bachelor</last_name>
    <phone>020-83710816</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua LI, PhD</last_name>
      <phone>020-83710825</phone>
      <email>llheliza@126.com</email>
    </contact>
    <contact_backup>
      <last_name>C</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu C, Ma X, Liu B, Chen C, Zhang H. HIV-1 functional cure: will the dream come true? BMC Med. 2015 Nov 20;13:284. doi: 10.1186/s12916-015-0517-y. Review.</citation>
    <PMID>26588898</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73.</citation>
    <PMID>9671771</PMID>
  </reference>
  <reference>
    <citation>Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015 Jan 15;517(7534):381-5. doi: 10.1038/nature14053. Epub 2015 Jan 7.</citation>
    <PMID>25561180</PMID>
  </reference>
  <reference>
    <citation>McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.</citation>
    <PMID>23401570</PMID>
  </reference>
  <reference>
    <citation>Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174. Epub 2013 Feb 14.</citation>
    <PMID>23459007</PMID>
  </reference>
  <reference>
    <citation>Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.</citation>
    <PMID>19213682</PMID>
  </reference>
  <reference>
    <citation>Leong YA, Atnerkar A, Yu D. Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the T(FH) Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary. Front Immunol. 2017 May 31;8:622. doi: 10.3389/fimmu.2017.00622. eCollection 2017. Review.</citation>
    <PMID>28620380</PMID>
  </reference>
  <reference>
    <citation>Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017 Feb;16(2):89-100. doi: 10.1038/nrd.2016.238. Epub 2016 Dec 23. Review.</citation>
    <PMID>28008168</PMID>
  </reference>
  <reference>
    <citation>Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.</citation>
    <PMID>12754504</PMID>
  </reference>
  <reference>
    <citation>Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295-300.</citation>
    <PMID>9360927</PMID>
  </reference>
  <reference>
    <citation>Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.</citation>
    <PMID>9371822</PMID>
  </reference>
  <reference>
    <citation>Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997 Nov 14;278(5341):1291-5.</citation>
    <PMID>9360926</PMID>
  </reference>
  <reference>
    <citation>Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 2013 Feb 1;10:11. doi: 10.1186/1742-4690-10-11. Review.</citation>
    <PMID>23375003</PMID>
  </reference>
  <reference>
    <citation>Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol. 2004 Aug;4(8):630-40. Review.</citation>
    <PMID>15286729</PMID>
  </reference>
  <reference>
    <citation>Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S; CHAVI Clinical Core B, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009 Jun 8;206(6):1253-72. doi: 10.1084/jem.20090365. Epub 2009 Jun 1.</citation>
    <PMID>19487423</PMID>
  </reference>
  <reference>
    <citation>Qiao L, Li Y, Xiong G, Liu X, He S, Tong X, Wu S, Hu H, Wang R, Hu H, Chen L, Zhang L, Wu J, Dai F, Lu C, Xiang Z. Effects of altered catecholamine metabolism on pigmentation and physical properties of sclerotized regions in the silkworm melanism mutant. PLoS One. 2012;7(8):e42968. doi: 10.1371/journal.pone.0042968. Epub 2012 Aug 24.</citation>
    <PMID>22937004</PMID>
  </reference>
  <reference>
    <citation>Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.</citation>
    <PMID>28003274</PMID>
  </reference>
  <reference>
    <citation>Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H. As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Res. 2013 Dec;100(3):688-97.</citation>
    <PMID>24416773</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>cART</keyword>
  <keyword>HIV-1 reservoir</keyword>
  <keyword>functional cure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

